Somatropin: research

Prescription human growth hormone, with no proven anti-aging benefit.

Also called: HGH, hGH, rhGH, recombinant human growth hormone, Genotropin, Humatrope, Norditropin, Omnitrope, Saizen, Zomacton, Serostim, Zorbtive, Nutropin AQ.

Growth hormone · Recombinant human growth hormone receptor agonist · Evidence: Approved drug.

At least 126 trials or study populations appear in seven key reviews. This minimum is not a complete count of separate human studies.

Studies

Somatropin dosage

Typical reported dose: Adult growth hormone deficiency: about 0.2 mg daily to start

  • Adult GHD: low daily start: A starting dose of approximately 0.2 mg/day (range, 0.15–0.30 mg/day). once daily, under the skin. Drug label. Studied in: Adults with confirmed GH deficiency. (source)
  • Adult GHD: Genotropin weight-based option: Start at not more than 0.04 mg/kg/week; increase to not more than 0.08 mg/kg/week at 4–8 week intervals. weekly total divided into daily injections, under the skin. Drug label. Studied in: Adults with confirmed GHD; weight dosing is less suitable in obesity. (source)
  • Adult GHD: Humatrope or Zomacton weight dosing: Initiate at 0.006 mg/kg daily; increase as needed to a maximum of 0.0125 mg/kg daily. once daily, under the skin. Drug label. Studied in: Adults with confirmed GHD; not recommended for obese patients. (source)
  • Adult GHD: historical Nutropin limits: Start at no more than 0.006 mg/kg/day; maximum 0.025 mg/kg/day at age ≤35, or 0.0125 mg/kg/day above 35. once daily, under the skin. Drug label. Studied in: Adults with GHD; Nutropin AQ NuSpin supply was discontinued. (source)
  • HIV wasting: daily Serostim: 0.1 mg/kg once daily, up to 6 mg: <35 kg, 0.1 mg/kg; 35–45 kg, 4 mg; 45–55 kg, 5 mg; >55 kg, 6 mg. once daily at bedtime, under the skin. Drug label. Studied in: Adults with HIV-associated wasting or cachexia. (source)
  • HIV wasting: alternate-day Serostim: A starting dose of 0.1 mg/kg every other day should be considered in patients at increased risk for adverse effects. every other day, under the skin. Drug label. Studied in: Adults with HIV wasting at higher risk of GH side effects, such as glucose intolerance. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Somatropin side effects and risks

Reported side effects

  • Swelling and fluid buildup: Adult GHD trials: peripheral swelling 17.5% GH vs 5.1% placebo at 6 months., moderate. Report new swelling; dose reduction often helps. New breathlessness needs urgent assessment. (source)
  • Joint pain: Adult GHD: 17.3% GH vs 4.2% placebo. HIV wasting daily dose: 36.4% vs 11.3%., moderate. Report persistent pain and review the dose. (source)
  • Hand tingling or numbness: Adult GHD: tingling 9.6% GH vs 1.9% placebo; carpal tunnel 2% in a 3031 person extension., moderate. Review dose and nerve symptoms promptly; weakness or persistent numbness needs assessment. (source)
  • Headache: Adult GHD: 9.9% GH vs 7.7% placebo., mild. A severe headache with vomiting or vision changes needs urgent care. (source)
  • Muscle pain: Adult GHD: 4.9% GH vs 1.6% placebo; HIV wasting daily dose: 30.4% vs 11.7%., moderate (source)
  • High blood sugar or new diabetes: Adult extension: diabetes 12/3031, 0.4%; all had risk factors. Rates depend strongly on dose and population., serious. Check glucose and HbA1c; diabetes medicines may need adjustment. (source)
  • Injection-site pain and local fat loss: Short bowel trial: injection site pain 31% GH alone vs 0% control. GHD injection site rates were not quantified., moderate. Rotate sites and review persistent redness, lumps or skin changes. (source)
  • Fluid retention at short-bowel doses: Peripheral edema: 69% GH, 81% GH plus glutamine, 11% control; 16, 16 and 9 participants., moderate (source)
  • Raised pressure around the brain: Reported with GH, usually within the first 8 weeks; an incidence rate is unavailable., serious. Stop and seek urgent assessment for headache with vomiting or vision change. (source)
  • Severe allergic reaction: Anaphylaxis and angioedema have been reported after marketing; frequency cannot be estimated., serious. Stop and get emergency care for throat swelling, wheezing or trouble breathing. (source)
  • Pancreatitis: Reported in children and adults; a reliable frequency is unavailable., serious. Get urgent care for severe ongoing upper belly pain or repeated vomiting. (source)
  • Unmasked thyroid or adrenal deficiency: unknown, serious. Review free T4 and adrenal function, especially with known pituitary disease. (source)
  • Hip growth-plate slip in children: unknown, serious. A new limp or hip or knee pain needs prompt assessment. (source)
  • Second tumors in childhood cancer survivors: Risk is most relevant after prior head radiation. Active cancer is contraindicated., serious (source)

Stop and get help if

  • Severe headache with vomiting, blurred vision or double vision: Stop GH and get urgent assessment for raised pressure around the brain.
  • Throat or face swelling, wheezing or trouble breathing: Stop GH and get emergency care.
  • Chest pain, fainting, sudden breathlessness or rapidly worsening swelling: Get emergency care.
  • Severe ongoing upper belly pain, especially with repeated vomiting: Stop GH and seek urgent assessment for pancreatitis.
  • Marked thirst or urination with vomiting, deep breathing or confusion: Get urgent care and check glucose; severe high blood sugar can be dangerous.
  • Sweating, shaking, confusion or collapse while also using insulin: Check glucose promptly. Persistent symptoms, inability to swallow or unconsciousness need emergency care.
  • Severe weakness, vomiting or fainting in someone with pituitary disease: Get urgent assessment for adrenal crisis and follow the prescribed adrenal emergency plan.
  • A new limp, hip pain or knee pain in a child receiving GH: Seek prompt assessment for a slipped growth plate.

Who should avoid it

  • activeCancer: Active cancer is a label contraindication. Any prior tumor must be inactive and its treatment completed before GH is considered.
  • other: High-dose GH increased deaths after major surgery, trauma or acute respiratory failure. Acute critical illness is a label contraindication.
  • diabeticRetinopathy: Active proliferative or severe nonproliferative diabetic retinopathy is contraindicated. Other retinopathy still needs clinician review.
  • other: Known serious allergy to somatropin or this product’s ingredients is contraindicated.
  • other: The Genotropin label contraindicates use for growth promotion in children with closed epiphyses (growth plates). This does not prohibit indicated growth-hormone replacement in adults with confirmed GH deficiency.
  • pregnant: Human pregnancy data are insufficient to determine developmental risk.
  • breastfeeding: The label reports limited milk data and no reported infant harm; safety evidence remains limited.
  • tryingToConceive: Fertility add-on studies do not establish fetal safety or a washout interval.
  • under18: Pediatric GH has specific approved growth-disorder uses that require specialist dosing and follow-up.
  • cancerHistory: Prior cancer, head radiation or a pituitary tumor needs recurrence surveillance. Childhood cancer survivors can develop second tumors.
  • diabetes: GH can reduce insulin sensitivity. Diabetes medicines may need adjustment; glucose should be monitored.
  • surgeryPlanned: Discuss planned surgery. Safety of continuing replacement GH during acute critical illness has not been established.
  • heartCondition: Fluid retention may matter more with heart disease. Review swelling, weight gain and breathlessness.
  • uncontrolledBloodPressure: Fluid retention and rapid weight gain need review before GH exposure or dose escalation.
  • kidneyDisease: Adult renal-impairment pharmacology data are limited. Childhood kidney-growth indications do not establish an adult dosing rule.
  • liverDisease: Adult liver-impairment pharmacology studies are lacking for Genotropin; no standard dose adjustment is established.
  • pancreatitisHistory: Pancreatitis has been reported. Review prior episodes and seek prompt care for new severe belly pain.
  • sleepApnea: Review snoring or breathing pauses. In Prader-Willi syndrome, severe obesity or major breathing impairment can preclude GH.
  • other: Severe obesity, prior upper-airway obstruction or sleep apnea, or severe breathing impairment in pediatric Prader-Willi syndrome is contraindicated.
  • other: GH may uncover low cortisol or low thyroid hormone in people with pituitary disease. Replacement doses may need adjustment.
  • testedAthlete: WADA prohibits GH at all times under S2.2.3, including use outside competition.

Interactions

  • Insulin and other glucose-lowering drugs: GH can raise blood sugar and change drug needs. Insulin or sulfonylureas can cause low sugar if dose needs fall after GH is reduced or stopped.
  • Glucocorticoids: GH may lower available cortisol and uncover adrenal insufficiency. Steroid replacement may need adjustment; excess steroids can blunt GH effects.
  • Oral estrogen: Oral estrogen can lower the IGF-1 response and increase GH dose needs. Starting, stopping or changing estrogen route can alter the required dose.
  • Thyroid hormone: GH may uncover central hypothyroidism. Free T4 and replacement dose may need review; extra thyroid hormone is not a routine GH add-on.
  • CYP-metabolized medicines: Somatropin may alter clearance of CYP-metabolized drugs. The label advises monitoring; the size and direction of each interaction are uncertain.
  • Other GH products or secretagogues: Duplicate GH exposure or adding release-stimulating drugs has no established healthy-adult benefit. Shared GH/IGF-1 effects may add risk.
  • IGF-1 drugs: The cited bodybuilding regimens have no controlled safety evidence. Adding another growth signal does not establish greater benefit or safer glucose control.

Product quality risks

  • FDA reports counterfeit and unapproved HGH entering the supply chain; an online vial or pen may not be a licensed product.
  • A 2009 mass-spectrometry study found distinct oxidation, deamidation and chain-cleavage patterns in counterfeit and reference GH products.
  • A 2025 analytical study detected GH in all 34 suspect products tested. Detection did not prove correct dose, sterility or clinical safety.
  • Product identity and purity tests do not by themselves establish potency, freedom from endotoxin or sterility.
  • An unknown vial’s storage history and mixing stability are unverified. Clear appearance cannot authenticate its contents.

How Somatropin works

It replaces GH directly, unlike peptides that ask the pituitary to release more. GH helps the body use fat and signals the liver and other tissues to make IGF-1, which supports growth. Too much can cause fluid buildup and make insulin work less well.

  • Growth hormone receptor: Triggers growth signals and changes how the body uses protein, fat and sugar.
  • IGF-1 pathway: Increases IGF-1 production in the liver and other tissues; supports bone and tissue growth.

Half-life: Genotropin: about 3 hours after an SC injection in adults with GHD; about 0.4 hours after IV dosing.

Gaps: The exact total of unique human studies is unknown. The numeric evidence count is a review-based lower bound, not a complete literature census. The seven review counts are 37 adult GHD, 18 older healthy populations, 27 young healthy samples, 10 ISS, 5 short bowel, 16 IVF and 13 burn trials. A broad PubMed query returned 2789 human trial/observational records. It includes comparator studies and repeat reports, so it was not used as the trial count. ClinicalTrials.gov returned 818 intervention-search records. These include GH analogues, comparators and unrelated interventions; they were not counted as 818 somatropin trials. Many historic approval trials predate registration. Some label entries pool several trials and do not provide each trial’s full safety or titration tables. All pivotal regional biosimilar programs and every later comparator trial have not been exhaustively extracted. This profile remains a draft. Anti-aging studies do not establish longer life, less disability, fewer heart attacks or long-term safety in healthy adults. Long-term replacement registries cannot establish safety of bodybuilding doses, online products or multi-drug stacks. The highest human dose across every route, schedule and indication was not established. An 8 mg/day short-bowel label cap is not a universal safe maximum. No controlled trial was found for GH with retatrutide, BPC-157, TB-500 or the reported insulin/IGF-1 bodybuilding stacks. Published GH-plus-testosterone research does not establish the safety of common bodybuilding combinations or doses. Pregnancy and milk data are limited. No reliable preconception washout interval was established; the reproductive cautions are precautions. Community commonness labels describe recurrence in this search, not measured use prevalence. No representative population survey or deduplicated user count was performed. No verified microdosing definition, optimal fasting window, five-on/two-off cycle or universal bodybuilding titration was found. Online vial strength, stability after mixing and sterility are unknown. Approved-product shelf lives cannot be transferred to those products. No somatropin-specific PCAC authorization was verified. FDA’s biologics exclusion governs 503A/503B; the schema has no “ineligible biologic” category. No comprehensive somatropin-specific poison-center series or current representative survey of counterfeit online pens was verified. Nitrogen-absorption numbers in the short-bowel Cochrane abstract are internally inconsistent; they were not transcribed. The SHOX registry and paper list different enrollment counts. The profile reports the paper’s 78 participants, including the Turner reference arm. Current US supply of every approved presentation was not established. Saizen’s public FDA label and registration table were reviewed.

Related to Somatropin

Somatropin: the short version

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.